Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Abstract

In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).

Keywords

Ejection fractionMedicineHeart failureSemaglutidePlaceboConfidence intervalBody mass indexWeight changeInternal medicineCardiologyObesityPhysical therapyWeight lossType 2 diabetesDiabetes mellitusLiraglutideEndocrinology

Affiliated Institutions

Related Publications

Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment

Barry A. Borlaug , Walter J. Paulus

Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF). Morbidity and mortality in HFpEF are similar to values observed in patients...

2010 European Heart Journal 1054 citations

Epidemiology and clinical course of heart failure with preserved ejection fraction

Carolyn S.P. Lam , Erwan Donal , Elisabeth Kraigher‐Krainer +1 more

Heart failure with preserved ejection fraction (HFPEF) is increasingly recognized as a major public health problem worldwide. Significant advances have been made in our understa...

2010 European Journal of Heart Failure 693 citations

A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction

Yogesh N.V. Reddy , Rickey E. Carter , Masaru Obokata +2 more

Background: Diagnosis of heart failure with preserved ejection fraction (HFpEF) is challenging in euvolemic patients with dyspnea, and no evidence-based criteria are available. ...

2018 Circulation 1101 citations

How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Burkert Pieske , Carsten Tschöpe , Rudolf A. de Boer +21 more

Abstract Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the ‘HFA–...

2019 European Heart Journal 1625 citations

Epidemiology of heart failure

Amy Groenewegen , Frans H. Rutten , Arend Mosterd +1 more

The heart failure syndrome has first been described as an emerging epidemic about 25 years ago. Today, because of a growing and ageing population, the total number of heart fail...

2020 European Journal of Heart Failure 1726 citations

Publication Info

Year: 2023
Type: article
Volume: 389
Issue: 12
Pages: 1069-1084
Citations: 1090
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1090

OpenAlex

Cite This

APA Style

                            
                                
                                    Mikhail Kosiborod, 
                                
                                    Steen Z. Abildstrøm, 
                                
                                    Barry A. Borlaug
                                
                                et al.
                            
                            (2023). 
                            Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. 
                            New England Journal of Medicine
                            , 389
                            (12)
                            , 1069-1084.
                            https://doi.org/10.1056/nejmoa2306963
                        

Identifiers

DOI: 10.1056/nejmoa2306963